Table of Contents As filed with the Securities and Exchange Commission on May 6, 2022...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 NOTICE OF EFFECTIVENESSEffective Date:September 28,
Table of Contents Filed pursuant to Rule 424(b)(3) Registration Number 333-259463...
Table of Contents As filed with the Securities and Exchange Commission on September 10, 2021...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ...
false 0001623613 0001623613 2020-11-16 2020-11-16 UNITED STATES SECURITIES AND EXCHANGE...
NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File...
0001623613FALSE2020Q312/31P3Y00016236132020-01-012020-09-30xbrli:shares00016236132020-10-31iso4217:USDxbrli:...
false000162361300016236132020-08-062020-08-06 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON...
Mylan Announces Third Quarter 2020 Financial Results and Looks Ahead to the Launch of Viatris Inc. PR...
Mylan Announces Appointment of Experienced Pharmaceutical Executive Bill Szablewski as Head of Capital Markets...
By Maria Armental Pfizer Inc. and Mylan NV have reached a deal with U.S. regulators over the spinoff of Pfizer's off-patent drugs business...
Mylan and Pfizer Receive Clearance from the U.S. Federal Trade Commission for Proposed Combination of Mylan...
Pfizer Announces Record Date for the Proposed Transaction Mylan N.V. (NASDAQ: MYL) and Pfizer Inc. (NYSE: PFE) today announced that the U.S...
Mylan and Development Partner, Synthon, Win Significant European Patent Office Ruling Related to Copaxone®...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.